mshivaiah, Author at Corcept Therapeutics

About mshivaiah

This author has not written his bio yet.
But we are proud to say that mshivaiah contributed 25 entries already.

Entries by mshivaiah

From Hazard Ratio to Clinical Impact: Number Needed to Treat in Platinum-Resistant Ovarian Cancer

Parthan et al. • 2026 • ISPOR EU

November 8, 2026

2-Year Overall Survival Results From DAZALS: A Phase 2, Randomized Controlled Trial of Dazucorilant, a Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

Ladha et al. • 2026 • NEALS

October 29, 2026

Budget Impact of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer: A US Payer Perspective

Bjerke et al. • 2026 • AMCP Nexus

October 27, 2026

Infusion Chair Time and Clinic Visits as Drivers of Healthcare Resource Utilization in Platinum-Resistant Ovarian Cancer

Arn et al. • 2026 • AMCP Nexus

October 27, 2026

Relacorilant Provides Significant Benefit Across Cardiometabolic Outcomes in Global Statistical Tests of the Placebo-controlled, Randomized-withdrawal GRACE Trial in Cushing Syndrome

Hand et al. • 2026 • CMHC

October 16, 2026

Characteristics Associated With Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disorders: Analyses From the MOMENTUM Study

Al Dhaybi et al. • 2026 • AHA HTN

October 8, 2026

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

DeFronzo et al. • 2026 • Heart in Diabetes

June 22, 2026

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

Lorusso et al. • 2026 • ESMO Gyn

June 18, 2026

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

Shahin et al. • 2026 • ESMO Gyn

June 18, 2026

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

DeFronzo et al. • 2026 • ENDO

June 15, 2026